Glenmark receives FDA acceptance to proceed with Phase 1/2 clinical study of GRC 54276 for advanced solid tumors and lymphomas
Glenmark Pharmaceuticals Ltd.'s subsidiary, Glenmark Specialty SA, has received acceptance from the U.S. Food and Drug Administration (FDA) for its...